Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Clin Lung Cancer. 2022 Apr 30;23(5):e317–e320. doi: 10.1016/j.cllc.2022.04.004

Figure 1: Schema and Systemic Option for ALLIANCE A082002 Trial:

Figure 1:

Treatment is to continue for up to 24 months or until disease progression or unacceptable adverse event. Patients will be followed for 5 years or until death, whichever comes first.

*Nivolumab/Ipilimumab (for squamous or non-squamous)

*Pembrolizumab/Carboplatin/Pemetrexed (for non-squamous)

*Nivolumab/Ipilimumab/Carboplatin/Pemetrexed (for non-squamous)

*Pembrolizumab/Carboplatin /Paclitaxel (for squamous)

*Pembrolizumab/Carboplatin/Nab-paclitaxel (for squamous)

*Nivolumab/Ipilimumab/Carboplatin/Paclitaxel (for squamous)